How much REGN fits your loss budget if the floor holds?
Volatility isn't risk. Ruin is. Choose the price you'd pay. The filings give us a modeled floor. You decide how much of your portfolio can be wrong. That — not a chart — sets the size.
Regeneron Pharmaceuticals, Inc. is a Healthcare company.
Its floor is the earnings power floor, modeled from its filings: $539.00 a share.
At the prior close of $805.02 on 2026-10-23, that floor is 33.0% below.
With a 3.0% loss limit, your loss budget allows 9.1% of your portfolio, and business quality allows up to 8.4%. Business quality is the tighter constraint.
REGN position size FAQ
How much REGN stock should I own?
That depends on the price you would pay and the loss you can accept. At the prior close of $805.02 and a 3.0% loss limit, the calculator's maximum is 8.4% of your portfolio. It is a ceiling on size, not a recommendation to buy.
What is Regeneron Pharmaceuticals, Inc.'s downside floor?
$539.00 a share: the earnings power floor, modeled from REGN's filings and recomputed 2026-10-23. Banks and insurers are held to book value; every other business to its earnings through a full cycle. A floor is a model, not a bound: the price can trade through it.
Why is REGN capped at 8.4%?
Its quality composite is 0.576 on a 0–1 scale, built from five ratios in its annual reports and graded against all companies, not just its sector. That composite keeps 70.3% of the 12.0% ceiling: 12.0% × 70.3% = 8.4%.
Does this tell me whether REGN is a buy?
No. It does not value the business. It sizes a position so one mistake cannot dominate your portfolio.
Other Healthcare stocks
Further reading
- Position sizing for value investorsWhy a risk budget built on the fall to a value floor beats gut feel.
- Business risk vs price riskThe two ways to lose money, and which one a floor measures.
- What business quality meansThe idea behind the quality score that caps every position.
- Seven steps before you buy a stockWhere sizing fits: it is the last of the seven.